

Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous Urticaria

NCT05916937

Status	RECRUITING
Phase	Phase 4
Sponsor	Simon Francis Thomsen
Enrollment	40 participants

Key Eligibility Criteria

Inclusion (5)

- A diagnosis of CSU according to the EAACI/GA2LEN/EDF/WAO guidelines.
- Age e 18 years.
- Omalizumab-naïve prior to initiating treatment with omalizumab.
- Background treatment with four antihistamines daily.
- Candidate for omalizumab treatment according to Danish guidelines.

Exclusion (8)

- Pregnant or breastfeeding women.
 - Planned pregnancy within the next 6 months.
 - Weight e 100 kilograms.
 - Presence of any other active skin disease or condition that may interfere with the assessment of CSU, such as atopic dermatitis, bullous pemphigoid, senile pruritus, or psoriasis.
 - Use of immunosuppressive drugs, such as prednisolone, azathioprine, methotrexate, or cyclosporine.
- ... and 3 more (see full listing online)

Locations (1 total)

Department of Dermatology, Bispebjerg Hospital, Copenhagen, Copenhagen N, Denmark